UB Paderborn / Katalog / Suche / in CDI

1 – 22 von 22

Sortiert nach

Changing bioperformance of TiO2 amorphous nanotubes as an effect of inducing crystallinity

Bioelectrochemistry (Amsterdam, Netherlands), 2012-10, Vol.87, p.124-131

2012

Volltextzugriff (PDF)

Comparison between corrosion behaviour of implant alloys Ti6Al7Nb and Ti6Al4Zr in artificial saliva

Materials and corrosion, 2013-06, Vol.64 (6), p.493-499

2013

Volltextzugriff (PDF)

Merit and demerit effects of silver nanoparticles in the bioperformance of an electrodeposited hydroxyapatite: nanosilver composite coating

Journal of nanoparticle research : an interdisciplinary forum for nanoscale science and technology, 2012-10, Vol.14 (10), p.1-10, Article 1152

2012

Volltextzugriff (PDF)

Prévalence de la toxicité hépatique des médicaments : ALAT et seuil d’alerte

Immuno-analyse & biologie spécialisée, 2011-04, Vol.26 (2), p.97-98

2011

Volltextzugriff (PDF)

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.CT125-CT125

2020

Volltextzugriff (PDF)

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5550-5550

2021

Volltextzugriff (PDF)

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Blood, 2020-11, Vol.136 (Supplement 1), p.29-30

2020

Volltextzugriff (PDF)

Attaquer ou ne pas attaquer? Le pharaon Kamosis au coeur d’un conflit idéologique (avec une nouvelle traduction de la « Geste de Kamosis »)

En détail – Philologie und Archäologie im Diskurs, 2021, Vol.7, p.703-718

2021

Volltextzugriff (PDF)

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

Blood, 2019-11, Vol.134 (Supplement_1), p.5329-5329

2019

Volltextzugriff (PDF)

138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

International journal of gynecological cancer, 2020-11, Vol.30 (Suppl 3), p.A61-A61

2020

Volltextzugriff (PDF)

PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES

Hematological oncology, 2019-06, Vol.37 (S2), p.324-325

2019

Volltextzugriff (PDF)

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Blood, 2014-12, Vol.124 (21), p.3483-3483

2014

Volltextzugriff (PDF)

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

Blood, 2014-12, Vol.124 (21), p.386-386

2014

Volltextzugriff (PDF)

T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts

The Journal of immunology (1950), 2010-07, Vol.185 (2), p.1132-1141

2010

Volltextzugriff (PDF)

T cell Epitope Specificity and Pathogenesis of MHV-1 Induced Disease in Susceptible and Resistant Hosts1

The Journal of immunology (1950), 2010-06, Vol.185 (2), p.1132-1141

2010

Volltextzugriff (PDF)

The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers

Clinical pharmacology in drug development, 2014-01, Vol.3 (1), p.51-56

2014

Volltextzugriff (PDF)

Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function

Journal of clinical pharmacology, 2003-12, Vol.43 (12), p.1361-1369

2003

Volltextzugriff (PDF)

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3028-3028

2005

Volltextzugriff (PDF)

Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers

Current therapeutic research, 1997-08, Vol.58 (8), p.504-514

1997

Volltextzugriff (PDF)

412 A phase I and pharmacokinetic study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

European journal of cancer supplements, 2004-09, Vol.2 (8), p.123-123

2004

Volltextzugriff (PDF)

Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers

Current therapeutic research, 1997-08, Vol.58 (8), p.492-503

1997

Volltextzugriff (PDF)

The Pharmacokinetics of Oral Isradipine in Normal Volunteers

Journal of clinical pharmacology, 1988-01, Vol.28 (1), p.36-42

1988

Volltextzugriff (PDF)

1 – 22 von 22

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(20)
Mit Volltextzugriff
(19)

Publikationsform

Artikel
(21)
Buchkapitel
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(9)
Life Sciences & Biomedicine
(7)
Pharmacology & Pharmacy
(5)
Biological And Medical Sciences
(4)
Humans
(4)
Medical Sciences
(4)
Pharmacology. Drug Treatments
(4)
Female
(3)
Adult
(2)
Bioavailability
(2)
Biocompatibility
(2)
Extended Release
(2)
Half-Life
(2)
Healthy Volunteers
(2)
Male
(2)
Materials Science
(2)
Materials Science, Multidisciplinary
(2)
Medicine, Research & Experimental
(2)
Neuropharmacology
(2)
Pharmacokinetics
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Changing bioperformance of TiO2 amorphous nanotubes as an effect of inducing crystallinity

Comparison between corrosion behaviour of implant alloys Ti6Al7Nb and Ti6Al4Zr in artificial saliva

Merit and demerit effects of silver nanoparticles in the bioperformance of an electrodeposited hydroxyapatite: nanosilver composite coating

Prévalence de la toxicité hépatique des médicaments : ALAT et seuil d’alerte

Abstract CT125: STRO-002-GM1, a first in human, phase 1 study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC), including fallopian tube or primary peritoneal cancers

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC)

Preliminary Results of an Ongoing Phase 1 Dose Escalation Study of the Novel Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with B-Cell Non-Hodgkin Lymphoma

Attaquer ou ne pas attaquer? Le pharaon Kamosis au coeur d’un conflit idéologique (avec une nouvelle traduction de la « Geste de Kamosis »)

Preliminary Results of a Phase 1 Dose Escalation Study of the First-in-Class Anti-CD74 Antibody Drug Conjugate (ADC), STRO-001, in Patients with Advanced B-Cell Malignancies

138 Phase 1 dose-escalation study of STRO-002, an anti-folate receptor alpha (FRα) antibody drug conjugate (ADC), in patients with advanced platinum-resistant/refractory epithelial ovarian cancer (OC)

PRELIMINARY RESULTS OF A PHASE 1 DOSE ESCALATION STUDY OF THE FIRST‐IN‐CLASS ANTI‐CD74 ANTIBODY DRUG CONJUGATE (ADC), STRO‐001, IN ADVANCED B‐CELL MALIGNANCIES

Phase Ib Study of the Novel Anti-CXCR4 Antibody Ulocuplumab (BMS-936564) in Combination with Lenalidomide Plus Low-Dose Dexamethasone, or with Bortezomib plus Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma

Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia

T cell epitope specificity and pathogenesis of mouse hepatitis virus-1-induced disease in susceptible and resistant hosts

T cell Epitope Specificity and Pathogenesis of MHV-1 Induced Disease in Susceptible and Resistant Hosts1

The effect of rifampin on the pharmacokinetics of sirolimus in healthy volunteers

Pharmacokinetics of E5564, a Lipopolysaccharide Antagonist, in Patients with Impaired Hepatic Function

Phase I study of AEE788, a novel multitargeted inhibitor of ErbB and VEGF receptor family tyrosine kinases: A pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen

Pharmacokinetics of once-daily venlafaxine extended release in healthy volunteers

412 A phase I and pharmacokinetic study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases

Bioavailability of once-daily venlafaxine extended release compared with the immediate-release formulation in healthy adult volunteers

The Pharmacokinetics of Oral Isradipine in Normal Volunteers

Suchergebnisse filtern